platinum has been researched along with ec20 folate peptide in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Burger, RA; Coleman, RL; Depasquale, SE; Gabrail, NY; Gersh, RH; Ghamande, SA; Gilbert, L; Harb, WA; Konstantinopoulos, PA; Kutarska, E; Leamon, CP; Lovejoy, CD; Messmann, RA; Morgenstern, DE; Naumann, RW; Nowara, E; Penson, RT; Sausville, EA; Symanowski, JT; Teneriello, MG | 1 |
1 trial(s) available for platinum and ec20 folate peptide
| Article | Year |
|---|---|
PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer.
Topics: Administration, Intravenous; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Folic Acid; Humans; Kaplan-Meier Estimate; Middle Aged; Nausea; Neutropenia; Oligopeptides; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Treatment Outcome; Vinca Alkaloids | 2013 |